Immunome (IMNM)

Executive Summary

Immunome is a clinical-stage oncology company specializing in first-in-class and best-in-class targeted cancer therapies, with a strong focus on antibody-drug conjugates (ADCs). Its lead asset, AL102 (varegacestat), is a gamma secretase inhibitor currently in a Phase 2/3 trial for desmoid tumors, a rare and often debilitating condition. Desmoid tumors have limited treatment options, and positive data from the ongoing trial could position AL102 as a potential standard of care. The company also has a diversified pipeline, including IM-1021, a ROR1-targeted ADC in Phase 1 for solid and hematologic malignancies, and a FAP-targeted radioligand therapy that recently cleared an IND to enter clinical trials. Immunome is led by an experienced management team with deep expertise in ADC development and commercialization. While the company has no approved products yet, its late-stage desmoid asset represents a significant near-term value driver. The balance of risk and reward is favorable, given the high unmet need in desmoid tumors and the potential for multiple pipeline readouts over the next 12-18 months. However, the company's early-stage ADC and radioligand programs are still preclinical or early-phase, adding execution risk. Overall, Immunome presents a compelling opportunity with a clear catalyst path.

Upcoming Catalysts (preview)

• Q4 2026AL102 Phase 2/3 desmoid tumor top-line data65% success
• H1 2027IM-1021 ROR1-targeted ADC Phase 1 dose-escalation update50% success
• H2 2027FAP-targeted radioligand therapy first-in-human data40% success